Breakthroughs in Targeted Therapy, Immunotherapy Reduce Cancer Deaths
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Breakthroughs in targeted therapy and immunotherapy are partly responsible for the recent decline in US cancer deaths, according to the AACR Cancer Progress Report 2023.
Language barriers may hinder access to cancer care before patients even encounter a physician, a new study suggests.
In a large study, most patients with T4 colon cancer did not receive guideline-recommended adjuvant chemotherapy.
Black patients are underrepresented in studies of multiple myeloma used to support IMWG guidelines, researchers found.
Deaths in patients with COVID-19 and cancer made up 81% of excess deaths among cancer patients during the first 2 years of the pandemic.
Among children receiving maintenance therapy for ALL, those living in extreme poverty had a nearly 2-fold greater risk of relapse than those not living in extreme poverty.
Black and Hispanic patients have a higher risk of death from second primary cancers than White and Asian/Pacific Islander patients, new data suggest.
Asian patients with de novo metastatic prostate cancer have better survival outcomes than White patients with the disease, according to a new study.
New research suggests that, in the United States, cancer was underdiagnosed during the first year of the COVID-19 pandemic.
LGBTQ+ adolescents and young adults with cancer face unique challenges in the health care setting, a review suggests.